PDE4

Assets acting on this target.

Class
Phosphodiesterase-4 inhibitor

Phosphodiesterase-4 (PDE4) is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a small signaling molecule inside cells that dampens inflammatory activity when its levels are high. PDE4 is expressed abundantly in immune cells such as monocytes, macrophages, and T cells, as well as in epithelial and skin cells, where it keeps cAMP levels in check. Inhibiting PDE4 prevents the breakdown of cAMP, allowing it to accumulate and reduce the production of pro-inflammatory mediators such as tumor necrosis factor and various interleukins. This rationale makes PDE4 inhibition broadly relevant to chronic inflammatory diseases, including inflammatory skin conditions like psoriasis and atopic dermatitis, inflammatory bowel conditions, and airway diseases such as chronic obstructive pulmonary disease, where excessive inflammatory signaling drives tissue damage and symptoms. Because PDE4 is expressed in many organ systems, inhibitors can be formulated for systemic use, applied topically to the skin, or engineered as prodrugs that release the active drug locally, such as within the colon, to concentrate the anti-inflammatory effect where disease is active while limiting exposure elsewhere in the body. This flexibility in delivery reflects an effort to preserve efficacy while managing the tolerability challenges associated with broader PDE4 inhibition.

By indication

Related mechanisms

PDE4 drugs compared

11 drugs, stage by indication
11 drugs acting on PDE4: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
apremilastOtezlaAmgensmall moleculeApprovedApproved in Psoriasis; Approved in Psoriatic Arthritis
crisaboroleEucrisaPfizersmall moleculeApprovedApproved in Atopic Dermatitis
difamilastMoizerto / AdqueyAcrotech Biopharma, Otsuka Holdingssmall moleculeApprovedApproved in Atopic Dermatitis
Roflumilast (Daliresp)DalirespAstraZenecasmall moleculeApprovedApproved in Chronic Obstructive Pulmonary Disease
Roflumilast (Zoryve foam)Zoryve foamArcutis Biotherapeutics, Sato Pharmaceutical Co., Ltd.small moleculeApprovedApproved in Psoriasis; Approved in Seborrheic Dermatitis
Roflumilast (Zoryve)ZoryveArcutis Biotherapeutics, Huadong Medicine, Sato Pharmaceutical Co., Ltd.small moleculeApprovedApproved in Atopic Dermatitis; Approved in Psoriasis
MufemilastTianjin Hemay Pharmaceuticalsmall moleculePhase 3Phase 3 in Psoriasis; Phase 3 in Ulcerative Colitis
Prifemilast (HPP737)cAMPfield Therapeutics, Newsoara Biopharma, vTv Therapeuticssmall moleculePhase 3Phase 3 in Psoriasis
ALTO-101Alto Neurosciencesmall moleculePhase 2Not recorded
MorcamilastMeiji Seika Pharmasmall moleculePhase 2Phase 2 in Psoriasis
PALI-2108Palisade BioSmall molecule (colon-targeted PDE4 inhibitor prodrug)Phase 2Phase 2 in Ulcerative Colitis; Phase 1 in Crohn's Disease

← all mechanisms